In that light, the GLP-1 rebound effect is not an obstacle but an opportunity to chart a new, holistic course in obesity care ...

GLP-1 meds may help — or harm — those with bipolar disorder. Read firsthand accounts of mood changes, weight loss, and side ...

For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

GLP-1 drugs such as Wegovy, Ozempic and Mounjaro are transforming weight loss and reshaping the food industry - driving ...

Research on weight loss drugs like Ozempic shows varied results for mental health impacts, with some patients experiencing mood and personality changes.

We are just starting to learn more about the systemic impact of these medications,” Dr. Shiara Ortiz-Pujols told The Post.

To fully understand the role of GLP-1RAs in managing diabetes and depression, further randomized controlled trials and long-term studies are needed, Guo added. Reference: Tang H, Lu Y, Donahoo WT, et ...

A bipartisan group of congressional lawmakers is calling on the Trump administration to address the continued sale of illicit, compounded GLP-1 products, warning that consumers may be accessing ...

The opioid epidemic, obesity, federal employee suicide and depression rates, and drug prices are on our readers’ minds.

There were associations for GLP-1 RA treatment vs placebo with improvements in restrained eating and emotional eating behavior and in mental health-related QOL. HealthDay News — For patients ...

GLP-1 receptor agonists are associated with improvements in restrained eating, emotional eating behavior, QOL. (HealthDay News) — For patients with overweight/obesity and/or diabetes ...